Compare MSC & IPSC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | MSC | IPSC |
|---|---|---|
| Founded | 2000 | 2019 |
| Country | Hong Kong | United States |
| Employees | N/A | N/A |
| Industry | Hotels/Resorts | Medicinal Chemicals and Botanical Products |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 352.4M | 405.8M |
| IPO Year | 2017 | 2021 |
| Metric | MSC | IPSC |
|---|---|---|
| Price | $1.77 | $2.04 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $4.25 |
| AVG Volume (30 Days) | 2.3K | ★ 1.3M |
| Earning Date | 04-30-2026 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 91.30 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $109,164,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 1556.76 |
| 52 Week Low | $1.58 | $0.44 |
| 52 Week High | $6.63 | $2.97 |
| Indicator | MSC | IPSC |
|---|---|---|
| Relative Strength Index (RSI) | 44.03 | 39.81 |
| Support Level | $1.58 | $1.91 |
| Resistance Level | $2.00 | $2.45 |
| Average True Range (ATR) | 0.12 | 0.13 |
| MACD | 0.02 | -0.02 |
| Stochastic Oscillator | 37.14 | 20.58 |
Studio City International Holdings Ltd is a gaming, retail, and entertainment resort located in Cotai, Macau. It operates Studio City Casino with around 250 mass-market gaming tables; including tables for VIP rolling chip operations, and 552 gaming machines. Studio City features luxury hotel rooms, diverse food and beverage establishments, and complementary retail space. In addition, the company offers non-gaming attractions, including the world's first figure-8 Ferris wheel, a deluxe nightclub and karaoke venue, a live performance arena, an outdoor and an indoor water park. Geographically, the company derives the majority of its revenue from the Macau region.
Century Therapeutics Inc is a biotechnology company harnessing the power of allogeneic pluripotent stem cell therapies to develop potentially curative cell therapy products for autoimmune diseases, including type 1 diabetes, or T1D, and cancer. Its beta islet, T cell and NK cell programs are allogeneic, meaning it is derived from healthy donors for use in any patient, rather than being sourced from an individual for their own specific use, as is the case with autologous T cells. The cell types it can generate from iPSCs, including iPSC-derived beta islet cells, iPSC-derived CD4+ and CD8+ alphabeta T cells, or alphabeta iT cells, and iPSC- natural killer cells, or iNK cells.